Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.